TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy Regimens
Brief Summary: In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety of gefitinib with docetaxel.


Options:
A: Intervention Type: DRUG; Name: Gefitinib or Docetaxel; Assigned to Arm(s): N/A
B: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib
C: Arm Label: 250 mg Gefitinib/500 mg Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib, Drug: Pemetrexed | Arm Label: 250 mg Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 250 mg Gefitinib, 250 mg Gefitinib/500 mg Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): 250 mg Gefitinib/500 mg Pemetrexed
D: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
D: Arm Label: Insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: Neutral Protamine Hagedorn (NPH) insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin detemir | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): Neutral Protamine Hagedorn (NPH) insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): Insulin detemir, Neutral Protamine Hagedorn (NPH) insulin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: Intensive therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle consultation: weight control, diet, exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Intensive therapy | Intervention Type: BEHAVIORAL; Name: Lifestyle consultation: weight control, diet, exercise; Assigned to Arm(s): Conventional therapy
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: Intensive Treatment; Type: OTHER; Interventions: Drug: multi-factorial intervention | Intervention Type: DRUG; Name: multi-factorial intervention; Assigned to Arm(s): Intensive Treatment
D: Arm Label: Nurse administered; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered | Arm Label: Nurse & BP monitor; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse administered, Device: BP Monitor | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home BP Monitor; Type: EXPERIMENTAL; Interventions: Device: BP Monitor | Intervention Type: BEHAVIORAL; Name: Nurse administered; Assigned to Arm(s): Nurse & BP monitor, Nurse administered | Intervention Type: DEVICE; Name: BP Monitor; Assigned to Arm(s): Home BP Monitor, Nurse & BP monitor

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: Levemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Levemir, NPH
B: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
C: Arm Label: Insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: Neutral Protamine Hagedorn (NPH) insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH insulin, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): Insulin detemir | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): Neutral Protamine Hagedorn (NPH) insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): Insulin detemir, Neutral Protamine Hagedorn (NPH) insulin
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including secondary prevention studies of diabetic retinopathy in both type 1 and type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A

Answer: B